Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Stephen Falk"'
Autor:
Jenny L Donovan, William Hollingworth, Caroline Wilson, Christopher Streets, S. M. Griffin, Tom Crosby, Dan Titcomb, Jane M Blazeby, R. Krysztopik, Sean Strong, CP Barham, Sara T Brookes, Stephen Falk, James L. Nicklin, A D Hollowood
Publikováno v:
British Journal of Cancer
Background: The optimal treatment for localised oesophageal squamous cell carcinoma (SCC) is uncertain. We assessed the feasibility of an RCT comparing neoadjuvant treatment and surgery with definitive chemoradiotherapy. Methods: A feasibility RCT in
Autor:
M Peterson, Juan W. Valle, Myrddin Rees, Louise Stanton, David Cunningham, Tamas Hickish, Timothy Iveson, Joanne Hornbuckle, Elizabeth Dixon, Tim Maughan, O. J. Garden, John Bridgewater, Rachel Butler, Derek A. O'Reilly, John N. Primrose, Louisa Little, Ajith K. Siriwardena, Stephen Falk, S Pugh, Megan Bowers, M Finch-Jones
Publikováno v:
The Lancet Oncology. 15:601-611
Summary Background Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy. The addition of cetuximab to the
Autor:
Tom, Waddell, Ian, Chau, David, Cunningham, David, Gonzalez, Alicia Frances Clare, Okines, Alicia, Frances, Clare, Okines, Andrew, Wotherspoon, Claire, Saffery, Gary, Middleton, Jonathan, Wadsley, David, Ferry, Wasat, Mansoor, Tom, Crosby, Fareeda, Coxon, David, Smith, Justin, Waters, Timothy, Iveson, Stephen, Falk, Sarah, Slater, Clare, Peckitt, Yolanda, Barbachano
Publikováno v:
BASE-Bielefeld Academic Search Engine
The Lancet Oncology
The Lancet Oncology
Summary Background EGFR overexpression occurs in 27–55% of oesophagogastric adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the anti-EGFR antibody panitumumab to epirubicin, oxaliplatin, and capecitabine (EOC) in
Autor:
Jakob R. Izbicki, Gary Middleton, Alan Anthoney, Paula Ghaneh, Harpreet Wasan, Kinnari Patel, David Cunningham, Olusola Olusesan Faluyi, Rubin Soomal, Thilo Hackert, John P. Neoptolemos, Christopher Halloran, Derek A. O'Reilly, Alec McDonald, Jonathan Wadsley, Yuk Ting Ma, Eftychia E. Psarelli, David Sherriff, Pascal Hammel, Markus W. Büchler, David Borg, Bengt Glimelius, Juan W. Valle, Roopinder Gillmore, Sharmila Sothi, Pehr Lind, Daniel H. Palmer, Tom Crosby, Tim Meyer, Richard J. Jackson, Paul Ross, Suzanne Darby, Stephen Falk, Sebastian Cummins
Publikováno v:
Lancet
Lancet (London, England)
European Study Group for Pancreatic Cancer 2017, ' Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. ', The Lancet, vol. 389, no. 10073, pp. 1011-1024 . https://doi.org/10.1016/S0140-6736(16)32409-6
Lancet (London, England)
European Study Group for Pancreatic Cancer 2017, ' Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. ', The Lancet, vol. 389, no. 10073, pp. 1011-1024 . https://doi.org/10.1016/S0140-6736(16)32409-6
Summary Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer. Other clinical trials
Autor:
Stephen Falk, H. Roach, Starrcat Investigators, B. A. Williams-Yesson, Nader K. Francis, E. J. Cooper, P. Ewings, George B. Hanna, Nicholas P. West, J. D. Foster
Publikováno v:
Techniques in coloproctology. 20(10)
The optimal time of rectal resection after long-course chemoradiotherapy (CRT) remains unclear. A feasibility study was undertaken for a multi-centre randomized controlled trial evaluating the impact of the interval after chemoradiotherapy on the tec
Publikováno v:
Cancer Chemotherapy and Pharmacology. 63:945-952
Diflomotecan, a homocamptothecin, targets DNA topoisomerase I. Previous clinical trials have demonstrated a variable degree of dose limiting toxicity. The purpose of this study was to further evaluate the safety and pharmacokinetic profile of a range
Autor:
Jaffer A. Ajani, Juan W. Valle, David Ferry, D Albert, E. Van Cutsem, J. Chick, H Glen, Stephen Falk, Alan Anthoney, Daniel W. Drolet, Martin Eatock
Publikováno v:
British Journal of Cancer
A two-stage Simon design was used to evaluate the response rate of OSI-7904L, a liposome encapsulated thymidylate synthase inhibitor, in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA), administered intravenously at 12 mg m(-2) ove
Autor:
Jane M Blazeby, Natalie S Blencowe, R. N. Whistance, Prem Chana, D. Stevens, Stephen Falk, N. A. C. S. Wong
Publikováno v:
Journal of the National Cancer Institute. 106(9)
Background The use of neoadjuvant therapy before surgery for gastrointestinal cancer is increasing; however, patients may not complete both treatment components. Understanding completion rates of each treatment stage is necessary for treatment evalua
Autor:
C Paul Barham, Chris Metcalfe, Kerry N L Avery, Tim Wheatley, Grant Sanders, Jane M Blazeby, Jenny L Donovan, Sian M Noble, George B. Hanna, R Berrisford, Richard Krysztopik, Dan Titcomb, Jackie Elliott, Christopher Streets, Stephen Falk, Robert D. Goldin, Andrew Hollowood
Publikováno v:
Trials
Background There is a need for evidence of the clinical effectiveness of minimally invasive surgery for the treatment of esophageal cancer, but randomized controlled trials in surgery are often difficult to conduct. The ROMIO (Randomized Open or Mini
Autor:
Mark Harrison, Tamas Hickish, David Propper, Ian Chau, Jim Cassidy, Iain R. Macpherson, Helen Finnigan, Timothy Iveson, Hilary Jones, Michael Braun, Hugo Ford, Stephen Falk, Vanessa Potter, Chooi Lee
Publikováno v:
European journal of cancer (Oxford, England : 1990). 50(18)
Purpose: This randomised phase II trial aimed to compare efficacy of the irreversible ErbB family blocker, afatinib, with cetuximab in patients with KRAS wild-type metastatic colorectal adenocarcinoma (mCRC) with progression following oxaliplatin-and